In conclusion, the results demonstrate that positive plasma mammaglobin A expression might serve as a biomarker of poor prognosis for breast carcinoma patients.
We have obtained CTCs-enriched blood fraction from 83 breast cancer patients in which we have tested the expression of epithelial, mesenchymal and general breast cancer CTCs markers (<i>MGB1/HER2/CK19/CDH1/CDH2/VIM/PLS3</i>), cancer stem cell markers (<i>CD44</i>, <i>NANOG</i>, <i>ALDH1</i>, <i>OCT-4</i>, <i>CD133</i>) and cluster formation gene (plakoglobin).
However, no significant cytotoxicity was observed under similar conditions in HLA-A2<sup>+</sup>/Mam-A<sup>-</sup> MCF-7 and MDA-MB-231 breast cancer cell lines.